leadf
logo-loader
viewBioPorto

BioPorto sees a 67% increase in NGAL-related revenue in its first quarter

BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive that its NGAL Test, which provides an early risk assessment of acute kidney injury, is seeing growing global interest both in the US and in Europe.

Larsen says rising demand for the test led to a 67% increase in NGAL-related revenue in the first quarter of 2020.

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment pleased Canada taking a look at allowing single...

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news the company is hailing the Canadian government’s decision to introduce legislation that would legalize single-event sports betting in Canada. Eghdami talks about why that...

1 day, 8 hours ago

2 min read